Progress of immunological surveillance in the treatment-free remission of chronic myelogenous leukemia

VernacularTitle:免疫监视在慢性粒细胞白血病无治疗缓解中的研究进展
Author: Lan YANG ¹ ; Lixia CAO ; Huijuan REN ; Yanqiu HAN
Author Information

1. 内蒙古医科大学附属医院血液科，呼和浩特　010050
Keywords: Leukemia, myelogenous, chronic, BCR-ABL positive; Immunologic surveillance; Remission induction; Protein kinase inhibitors
From: Journal of Leukemia & Lymphoma 2022;31(8):502-505
CountryChina
Language:Chinese
Abstract: With the wide application of tyrosine kinase inhibitor (TKI), to obtain treatment-free remission (TFR) has gradually become the long-term goal for patients with chronic myelogenous leukemia (CML). Self-renewing leukemia stem cells during disease progression are related with the recurrence, and surveillance of residual leukemic cells is hypothesized to be one of the critical factors in successful TFR. On the way to obtain TFR, many breakthroughs have been made in innate and adaptive immunity of CML cells. This paper reviews the immune function of CML patients, the role of the immune markers in maintaining TFR, and the exploration of TKI combined with new immunomodulator therapy to achieve a greater degree of TFR.